Lituanie - lituanien - SMCA (Valstybinė vaistų kontrolės tarnyba)

pekana naturheilmittel gmbh - acidum benzoicum e resina d4/acidum nitricum d4/apis mellifica d4/lytta vesicatoria d4/populus tremuloides d2/pulsatilla pratensis d4/zingiber officinalis d3/solidago virgaurea Ø - geriamieji lašai (tirpalas) - 0,125 g/0,125 g/0,1 g/0,115 g/0,13 g/0,12 g/0,13 g/0,155 g/g

Lituanie - lituanien - SMCA (Valstybinė vaistų kontrolės tarnyba)

biologische heilmittel heel gmbh - acidum phosphoricum d4/strychnos ignatii d4/sepia officinalis d4/kalium bromatum d4/zincum isovalerianicum d4 - tabletės - 60 mg/60 mg/60 mg/30 mg/30 mg

Union européenne - lituanien - EMA (European Medicines Agency)

novo nordisk a/s - semaglutidas - obesity; overweight - antikoaguliantų preparatai, išskyrus dietos produktai - wegovy is indicated as an adjunct to a reduced-calorie diet and increased physical activity for weight management, including weight loss and weight maintenance, in adults with an initial body mass index (bmi) of- ≥30 kg/m² (obesity), or- ≥27 kg/m² to.

Lituanie - lituanien - SMCA (Valstybinė vaistų kontrolės tarnyba)

bayer ag - gadotero rūgštis - injekcinis tirpalas - 0,5 mmol/ml - gadoteric acid

Union européenne - lituanien - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains), attenuated chlamydophila felis (905 strain), attenuated feline panleucopenia virus (pli iv) - immunologicals už felidae, - katės - active immunisation of cats aged eight weeks and older:• against feline viral rhinotracheitis to reduce clinical signs;• against calicivirus infection to reduce clinical signs;• against chlamydophila felis infection to reduce clinical signs;• against feline panleucopenia to prevent mortality and clinical signs. onsets imuniteto parodė, vieną savaitę po pirminės vakcinacijos kurso, rinotracheito, calicivirus, chlamydophila felis ir panleucopenia komponentai. the duration of immunity is one year after the last re-vaccination for the chlamydiosis component, and oneyear after primary vaccination and three years after the last re-vaccination for the rhinotracheitis, calicivirosis and panleucopenia components.

Union européenne - lituanien - EMA (European Medicines Agency)

pharmathen s.a. - ibandrono rūgštis - hypercalcemia; fractures, bone; neoplasm metastasis; breast neoplasms - narkotikai kaulų ligų gydymui - concentrate for solution for infusion prevention of skeletal events (pathological fractures, bone complications requiring radiotherapy or surgery) in patients with breast cancer and bone metastases. gydymo auglio sukeltas hypercalcaemia su arba be metastazių. film-coated tablets prevention of skeletal events (pathological fractures, bone complications requiring radiotherapy or surgery) in patients with breast cancer and bone metastases.

Lituanie - lituanien - SMCA (Valstybinė vaistų kontrolės tarnyba)

teva b.v. - oktreotidas - milteliai ir tirpiklis pailginto atpalaidavimo injekcinei suspensijai - 10 mg - octreotide

Lituanie - lituanien - SMCA (Valstybinė vaistų kontrolės tarnyba)

teva b.v. - oktreotidas - milteliai ir tirpiklis pailginto atpalaidavimo injekcinei suspensijai - 20 mg - octreotide

Union européenne - lituanien - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains), attenuated feline panleucopenia virus (pli iv), felv recombinant canarypox virus (vcp97) - immunologicals už felidae, - katės - active immunisation of cats aged 8 weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs ;against feline panleucopenia to prevent mortality and clinical signs;against leukaemia to prevent persistent viraemia and clinical signs of the related disease. onsets of immunity are 1 week after primary vaccination course for rhinotracheitis, calicivirus and panleucopenia components, and 2 weeks after primary vaccination course for feline leukaemia component. the duration of immunity is one year after the last re-vaccination for the feline leukaemia component, and one year after primary vaccination course and three years after the last re-vaccination for the rhinotracheitis, calicivirosis and panleucopenia components.

Union européenne - lituanien - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains), attenuated feline panleucopenia virus (pli iv), felv recombinant canarypox virus (vcp97), attenuated chlamydophila felis (905 strain) - immunologicals už felidae, - katės - active immunisation of cats aged 8 weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs;against chlamydophila felis infection to reduce clinical signs;against feline panleucopenia to prevent mortality and clinical signs;against leukaemia to prevent persistent viraemia and clinical signs of the related disease. onsets of immunity are 1 week after primary vaccination course for rhinotracheitis, calicivirus, chlamydophila felis and panleucopenia components, and 2 weeks after primary vaccination course for feline leukaemia component. the duration of immunity is one year after the last re-vaccination for the chlamydiosis and feline leukaemia components, and one year after primary vaccination course and three years after the last re-vaccination for the rhinotracheitis, calicivirosis and panleucopenia components.